May 2013
BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p6
The article discusses comments by several pharmaceuticals professionals relating to clinical trials of drugs including Stanley Crooke, at Isis Pharmaceuticals Inc., Alon Moran at Enlivex Therapeutics Ltd., and Carlo Toniatti, at the University of Texas MD Anderson Cancer Center.


Related Articles

  • Drug Trials and Older People. Witham, Miles D. // Drugs & Aging;2011, Vol. 28 Issue 8, p679 

    No abstract available.

  • From the Editor's desk. Tyrer, Peter // British Journal of Psychiatry;Mar2010, Vol. 196 Issue 3, p254 

    An introduction to the journal is presented in which the editor discusses reports published within the issue including the importance of attention to methodology in clinical trials, restriction of publication bias to drug trials, and the mental ill-effects of neglect, abuse, and deprivation.

  • National Pharmaceutical Institute answers allegations.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p7 

    Reports on the Hungarian National Pharmaceutical Institute's denial that dangerous drug experiments are being carried out on unsuspecting patients. Rules concerning clinical trials in Hungary; Reasons that make Europe an easier place to find clinical trial patients.

  • ADVANCE-2: Apixaban had favorable risk-benefit profile compared with enoxaparin.  // Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p23 

    The article discusses the results of a clinical drug trial which revealed the therapeutic use of apixaban for thromboprophylaxis after total knee replacement.

  • New rules for industry-sponsored articles.  // Drug Utilization Review;Oct2001, Vol. 17 Issue 10, p77 

    Discusses the rules for drug industry-sponsored articles on clinical trials enforced by the joint editorial of 12 medical journals. Reasons for implementing the rules; Details of the rules; Journals that participated in the effort.

  • Clinical trials not to be taken lightly. White, Phil // New Zealand Doctor;10/8/2008, p13 

    The author expresses his view regarding phase 3 and 4 drug trials in New Zealand, which are being promoted as a business opportunity for general practice. According to the author, these trials should not be seen as low risk as it is the first opportunity to test the drugs on humans, and it...

  • Trial Scorecards.  // Cardiology Today;Sep2013, Vol. 16 Issue 9, p12 

    This section presents a summary of the results of several clinical trials involving cardiovascular drugs, as of September 2013, including the efficacy of apixaban for treatment of thrombosis and the treatment of chronic ischemic myocardium with combined extraporporeal shock wave therapy and...

  • Testing Products in China.  // Pharmaceutical Executive;May2002, Vol. 22 Issue 5, p20 

    Reports on the move of U.S. pharmaceutical companies towards testing products in China. Factors that make Chinese research trials relatively easy and affordable; Information on some companies that conducted trials in the country; Characteristics of drug testing in China.

  • Half of children's medicines still untested.  // Paediatric Nursing;Apr2006, Vol. 18 Issue 3, p4 

    The article discusses a report by the British House of Lords which concludes that there is an urgent need to take action at a European level to promote and govern clinical trials of medicines on children. More than 50 per cent of all medicines given to children and around 90 per cent of those...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics